Mark Verratti - Mar 13, 2025 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role
Chief Commercial Officer
Signature
By: Justin Hunter For: Mark Verratti
Stock symbol
MYGN
Transactions as of
Mar 13, 2025
Transactions value $
-$96,430
Form type
4
Date filed
3/17/2025, 04:19 PM
Previous filing
Mar 4, 2025
Next filing
Mar 25, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Award $0 +99.2K +32.85% $0.00 401K Mar 13, 2025 Direct F1
transaction MYGN Common Stock Tax liability -$58.9K -5.85K -1.46% $10.07 395K Mar 14, 2025 Direct F2
transaction MYGN Common Stock Tax liability -$37.6K -3.73K -0.94% $10.07 392K Mar 15, 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.
F2 Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 14, 2025.